Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Extensive-Stage Small Cell Lung Cancer (ESCLC) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages […]
